Hengrui Gets First OK for a PD-L1/TGF-Beta Drug for Cancer

Why It Matters

The approval introduces a novel immunotherapy that could reshape gastric cancer treatment in the world’s largest patient market, validating the bispecific checkpoint‑TGF‑beta strategy after high‑profile failures.

Key Takeaways

• First global PD‑L1/TGF‑beta inhibitor approval
• Approved for frontline gastric/GEJ adenocarcinoma in China
• Phase 3 RELIGHT shows 34% overall‑survival improvement
• Bispecific design targets immune suppression and tumor microenvironment
• China accounts for roughly 44% of global gastric cancer cases

Pulse Analysis

Gastric cancer remains a major health challenge, with nearly one million new diagnoses annually and a mortality burden that places it among the top five cancer killers worldwide. In China, the disease is especially prevalent, driven by Helicobacter pylori infection, dietary factors, and lifestyle risks, accounting for up to 44% of global cases. Traditional chemotherapy has offered limited gains, prompting a surge in immunotherapy research that seeks to unleash the immune system while mitigating the tumor’s suppressive environment.

Retlirafusp alfa distinguishes itself by fusing a PD‑L1‑blocking antibody with the extracellular domain of the TGF‑beta type 2 receptor, simultaneously lifting immune checkpoints and dampening TGF‑beta‑driven fibrosis and immune evasion. The phase 3 RELIGHT trial, conducted in 737 Chinese patients, delivered a compelling overall‑survival advantage: median survival extended from 11.2 to 15.8 months, with even larger benefits in PD‑L1‑positive and liver‑metastatic subgroups. Compared with existing PD‑1 inhibitors, the bispecific approach offers a mechanistic edge, potentially overcoming resistance mechanisms that have limited monotherapy efficacy.

The commercial implications are significant. Hengrui’s success not only grants it a first‑in‑class asset in a market where multinational giants have withdrawn, but it also positions the company to leverage the drug beyond China, pending regulatory approvals in other high‑incidence regions. Investors and competitors will watch closely as Hengrui expands clinical programs, possibly targeting other solid tumors where TGF‑beta plays a pivotal role. The approval underscores a broader industry shift toward multifunctional biologics, suggesting that bispecific checkpoint inhibitors could become a new frontier in precision oncology.